Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocircuits' point-of-care (POC) system gets FDA approval:

This article was originally published in Clinica

Executive Summary

The US FDA has cleared Biocircuits' point-of-care immunodiagnostic platform, IOS; the combined T4 and T uptake assay, and a T4-only assay. Biocircuits is developing cartridges for additional physicians' office tests, including one for thyroid stimulating hormone, a serum pregnancy test, and a quantitative hCG test. Approximately 45,000 small to medium sizes practices perform clinical chemistry and haematology testing but do not have immunodiagnostic capabilities. The IOS system will cost around $6,000 and gives results in 20-30 minutes.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094400

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel